Dr. Ryan Lucas Ottwell , DO
Dermatology β’ Tulsa, OK
3915 E 51st St
Tulsa, OK 741353605
This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.
-
NPI assigned on April 22, 2021; this date does not establish years in practice.
-
Published CMS data list 74 Medicare Part D prescriptions, including refills, in 2024.
Source: CMS, Medicare Part D Prescribers β by Provider and Drug, 2024. Published rows only; this is not a quality measure.
-
Published Part D records, 2024:
- Ketoconazole β 33 prescription fills, including refills.
- Triamcinolone Acetonide β 16 prescription fills, including refills.
- Dupixent Pen (Dupilumab) β 14 prescription fills, including refills.
Source: CMS, Medicare Part D Prescribers β by Provider and Drug, 2024. Drug names come from pharmacy claims. Listing a drug here is not an endorsement or a recommendation.
See all 4 records in the table Β· Guide: How to read Medicare Part D prescriber data
-
Fewer Part D prescriptions than 90% of clinicians listed under Dermatology in Tulsa, OK (2024, 24 clinicians with data). Median for this group: 1,090. Middle half: 345 to 1,571.
Fewer Part D prescriptions than 85% of clinicians listed under Dermatology in Oklahoma (2024, 97 clinicians with data). Median for this group: 550. Middle half: 227 to 1,127.
Source: CMS, Medicare Part D Prescribers β by Provider and Drug, 2024. Billing and prescribing volume is not a quality rating.
-
Medicare Part D prescriptions went from 15 in 2023 to 74 in 2024.
Source: CMS, Medicare Part D Prescribers β by Provider and Drug, 2023β2024.
Practice Location & Contact Primary Location
3915 E 51st St
Tulsa, OK 741353605
Matched by practice address or phone in NPPES. A shared address or phone does not confirm that this clinician works there.
Medicare Profile & Education
Source: CMS Doctors and Clinicians National Downloadable File
2021
What Public CMS Data Show
Dermatology: NPPES taxonomy is a reported classification, not proof of board certification.
30-day fills
95 standardized 30-day fills in 2024
CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.
What this does not show: 30-day fills
It is not a count of patients and not a measure of quality.
Part D drug cost
$49,829 in 2024
The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.
It shows the total spending on drugs this clinician prescribed, not what any one patient paid.
What this does not show: Part D drug cost
A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.
Source: CMS, Medicare Part D Prescribers β by Provider and Drug, 2024.
Open Payments general payments, program year 2025
All general payments: $1,216.33 across 25 records.
By nature of payment
- Food and Beverage: $1,142.83 across 24 records.
- Education: $73.50 across 1 record.
Reporting-company totals (3 largest of 9)
- ABBVIE INC.: $411.56 across 10 records.
- Sanofi and Genzyme US Companies: $362.84 across 5 records.
- Arcutis Biotherapeutics, Inc.: $115.01 across 1 record.
A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.
Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).
Years since graduation
5 years (graduated 2021)
CMS Doctors and Clinicians data list 2021 as the year this clinician finished professional school.
It tells you roughly how long ago the clinician finished school.
What this does not show: Years since graduation
It is not the number of years in practice, and more years does not mean better care.
Source: CMS Doctors and Clinicians National Downloadable File.
NPI first issued
2021
The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.
What this does not show: NPI first issued
NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.
Source: CMS NPPES NPI Registry.
Accepts Medicare assignment
CMS data list this clinician as accepting Medicare assignment. This means agreeing to take the Medicare-approved amount as full payment for covered services.
With Original Medicare, you usually pay only your deductible and coinsurance, and the office sends the claim to Medicare for you.
Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.
Source: CMS Doctors and Clinicians; Medicare.gov, βDoes your provider accept Medicare as full payment?β
No telehealth indicator
CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.
Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians.
Enrolled in Medicare (PECOS)
Dr. Ottwell has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.
It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Can order Medicare-covered services
CMS lists Dr. Ottwell as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.
Medicare pays for these items and services only when they are ordered by an eligible clinician.
What this does not show: Can order Medicare-covered services
It does not mean the clinician offers these services directly.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Compared with the same specialty in Tulsa and Oklahoma
Billing and prescribing volume is not a quality rating.
Medicare Part D prescriptions
Fewer Part D prescriptions than 90% of clinicians listed under Dermatology in Tulsa, OK (2024, 24 clinicians with data). Median for this group: 1,090. Middle half: 345 to 1,571.
Fewer Part D prescriptions than 85% of clinicians listed under Dermatology in Oklahoma (2024, 97 clinicians with data). Median for this group: 550. Middle half: 227 to 1,127.
Part D drug cost
A lower Part D drug cost than 70% of clinicians listed under Dermatology in Tulsa, OK (2024, 24 clinicians with data). Median for this group: $229,598. Middle half: $43,059 to $436,460.
Close to the middle for clinicians listed under Dermatology in Oklahoma (2024, 97 clinicians with data). Median for this group: $100,619. Middle half: $7,744 to $312,562.
33 active clinicians are listed under Dermatology with a practice address in Tulsa, OK (125 in Oklahoma).
Addresses are self-reported to NPPES and may be out of date.
Telehealth indicator in Tulsa
3% of these 33 clinicians have the CMS telehealth indicator.
78.8% of these 33 clinicians are listed by CMS as accepting Medicare assignment.
CMS data by year
Changes may reflect reporting, coverage or privacy limits, not changes in care quality.
-
Medicare Part D prescriptions
Medicare Part D prescriptions went from 15 in 2023 to 74 in 2024.
- 2023: 15
- 2024: 74
-
30-day fills
30-day fills went from 15 in 2023 to 95 in 2024.
- 2023: 15
- 2024: 95
-
Part D drug cost
Part D drug cost went from $301 in 2023 to $49,829 in 2024.
- 2023: $301
- 2024: $49,829
-
Industry payments (Open Payments)
Industry payments (Open Payments) went from $121.82 in 2024 to $1,216.33 in 2025.
- 2024: $121.82
- 2025: $1,216.33
Sources: CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.
Text: T-MedInfo Β· Report an error.
Pharma & Medical Device Financial Disclosures
Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments
Program year 2025 (payments made January 1 β December 31, 2025): 25 records totaling $1,216.33.
| Manufacturer | Payment Nature | Product | Type | Amount ($) |
|---|---|---|---|---|
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
β | General | $125.00 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
RINVOQ | General | $124.21 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $123.63 |
| Arcutis Biotherapeutics, Inc. |
Food and Beverage
In-kind items and services
|
Zoryve | General | $115.01 |
| Bristol Myers Squibb Company |
Food and Beverage
Cash or cash equivalent
|
Sotyktu | General | $99.96 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $97.67 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
β | General | $93.11 |
| Regeneron Pharmaceuticals, Inc. |
Education
In-kind items and services
|
DUPIXENT | General | $73.50 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $35.64 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $31.22 |
| SUN PHARMACEUTICAL INDUSTRIES INC. |
Food and Beverage
In-kind items and services
|
ILUMYA | General | $26.58 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
RINVOQ | General | $25.58 |
| LEO Pharma Inc. |
Food and Beverage
In-kind items and services
|
ANZUPGO | General | $25.31 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $24.71 |
| LEO Pharma Inc. |
Food and Beverage
In-kind items and services
|
ANZUPGO | General | $24.37 |
| LEO Pharma Inc. |
Food and Beverage
In-kind items and services
|
ANZUPGO | General | $21.43 |
| LEO Pharma Inc. |
Food and Beverage
In-kind items and services
|
ANZUPGO | General | $21.15 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $19.88 |
| Novartis Pharmaceuticals Corporation |
Food and Beverage
In-kind items and services
|
Rhapsido | General | $18.60 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
RINVOQ | General | $16.47 |
| Eli Lilly and Company |
Food and Beverage
In-kind items and services
|
TALTZ | General | $16.02 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $15.46 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
SKYRIZI | General | $15.38 |
| ABBVIE INC. |
Food and Beverage
In-kind items and services
|
RINVOQ | General | $13.65 |
| Sanofi and Genzyme US Companies |
Food and Beverage
In-kind items and services
|
DUPIXENT | General | $12.79 |
Source: CMS Open Payments, program year 2025, released June 30, 2026.
Medicare Part D Prescribing Profile & Medications
Medicare Part D prescriptions filled, including refills, in 2024.
| Brand Name | Generic Name | Prescriptions | Day Supply | Total Cost | Patients |
|---|---|---|---|---|---|
| Ketoconazole | Ketoconazole | 33 | 1,806 | $472.75 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 516 | $118.77 | 12 |
| Dupixent Pen | Dupilumab | 14 | 364 | $49,186.90 | β |
| Hydrocortisone | Hydrocortisone | 11 | 160 | $50.26 | β |
Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits
Specialties & License Numbers Reported to NPPES
Self-certified to NPPES: 2025-06-30NUCC Taxonomy Code: 207N00000X
A dermatologist is trained to diagnose and treat pediatric and adult patients with benign and malignant disorders of the skin, mouth, external genitalia, hair and nails, as well as a number of sexually transmitted diseases. The dermatologist has had additional training and experience in the diagnosis and treatment of skin cancers, melanomas, moles and other tumors of the skin, the management of contact dermatitis and other allergic and nonallergic skin disorders, and in the recognition of the skin manifestations of systemic (including internal malignancy) and infectious diseases. Dermatologists have special training in dermatopathology and in the surgical techniques used in dermatology. They also have expertise in the management of cosmetic disorders of the skin such as hair loss and scars and the skin changes associated with aging.
Medicare (PECOS) Enrollment & Ordering Eligibility
Source: CMS PECOSPRACTITIONER - DERMATOLOGY
I20250623002083
OK
7810370566
Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.
Clinicians Sharing This Practice Address or Phone
Clinicians sharing this NPPES address, phone or fax; a shared contact does not mean they work together.
Dermatology
Doctor of Medicine (M.D.)
Dermatology
Doctor of Medicine (M.D.)
Dermatology
Doctor of Medicine (M.D.)
Career & Practice History Timeline
Changes recorded in monthly NPPES data files: addresses, names, credentials, specialties and NPI status
Registered at 3915 E 51ST ST, TULSA, OK 741353605 (Tel: 9187495714)
Registered at 3915 E 51ST ST, TULSA, OK 741353605 (Tel: 9187495714)
Dermatology (license number reported to NPPES: OK 8925)
NPI status registered as active in NPPES database
Registered at 4502 E 41ST ST, TULSA, OK 741352536 (Tel: 9186194400)
Registered at 1425 W 78TH ST APT NO822, TULSA, OK 741324619 (Tel: 9189918718)
Recorded as RYAN OTTWELL, DO
Student in an Organized Health Care Education/Training Program
First registered as active Individual Practitioner in NPPES Database.
NPI Administrative Meta
Other Dermatology Specialists in Tulsa
- Dr. Miranda Smith, MD
- Dr. Johnathan Ledet, MD
- Dr. Michelle Walters, MD
- Dr. Bernard Robinowitz, MD
- Dr. David Adelson, MD
- Dr. Kristen Rice, MD
Mailing Address
3915 E 51st St
Tulsa, OK 741353605
Phone: 9187495714